Related Experiment Videos
Dosimetry parameters of BARC OcuProsta I-125 seed source
1Radiological Physics & Advisory Division, Bhabha Atomic Research Centre, Mumbai, India. sdsharma_barc@rediffmail.com
Summary
A new Iodine-125 seed, OcuProsta, was characterized for ophthalmic and interstitial brachytherapy. Dosimetry parameters, including dose rate constant and radial dose function, were determined experimentally and via Monte Carlo simulation, showing good agreement with other 125I seeds.
Area of Science:
- Medical Physics
- Radiological Sciences
- Nuclear Medicine
Background:
- Brachytherapy utilizes sealed radioactive sources for localized radiation delivery.
- Accurate dosimetry is critical for effective and safe brachytherapy treatment planning.
- New radioactive seed sources require thorough characterization before clinical implementation.
Purpose of the Study:
- To determine and recommend dosimetry parameters for the newly developed OcuProsta Iodine-125 seed source.
- To validate experimental dosimetry measurements using Monte Carlo simulations.
- To compare the OcuProsta seed's dosimetry characteristics with established 125I seed sources.
Main Methods:
- Experimental determination of dosimetry parameters using thermoluminescent dosimeters (TLD).
- Monte Carlo (MC) simulations to calculate AAPM TG 43 dosimetry parameters.
- Comparison of measured and simulated data for dose rate constant, radial dose function, and anisotropy function.
Main Results:
- The mean dose rate constant (DRC) for OcuProsta seed was recommended as 0.96 cGyh(-1)U(-1).
- Measured and MC calculated dosimetry parameters showed good agreement.
- OcuProsta seed's DRC is comparable to other 125I seeds (Amersham 6711, Best 2301, Syncor PharmaSeed, Isotron selectSeed).
- Radial dose function and anisotropy function showed minor differences (up to 10% and 7-13%, respectively) compared to similar seeds.
Conclusions:
- The OcuProsta 125I seed source is suitable for ophthalmic and interstitial brachytherapy applications.
- The determined dosimetry parameters provide a basis for clinical use and treatment planning.
- Further research may focus on long-term performance and clinical outcomes.